Table 3.
Results of the univariable and multivariable Cox hazard models for predicting any infection, infection requiring hospitalization and COVID-19 in pwMS treated with ocrelizumab.
| Univariable COX hazard model | Multivariable Cox hazard model | |||||
|---|---|---|---|---|---|---|
| HR | 95% C.I. for HR | p value | HR | 95% C.I. for HR | p value | |
| Any infection | ||||||
| Age | 0.998 | 0.973-1.024 | 0.881 | |||
| Sex | 2.561 | 1.382-4.774 | 0.003 | |||
| Disease duration | 1.01 | 0.968-1.055 | 0.633 | |||
| EDSS | 0.962 | 0.822-1.127 | 0.635 | |||
| MS phenotype | 0.832 | 0.479-1.445 | 0.514 | |||
| Δ IgM | 0.841 | 0.387-1.829 | 0.663 | |||
| Δ IgG | 0.83 | 0.649-1.063 | 0.14 | |||
| Infection requiring hospitalization | ||||||
| Age | 1.099 | 1.030-1.173 | 0.004 | 1.086 | 1.018-1.159 | 0.013 |
| Sex | 0.641 | 0.169-2.431 | 0.513 | |||
| Disease duration | 0.216 | 0.963-1.180 | 0.216 | |||
| EDSS | 0.953 | 0.626-1.452 | 0.824 | |||
| MS phenotype | 1.913 | 0.478-7.655 | 0.359 | |||
| Δ IgM | 11.321 | 1.836-69.824 | 0.009 | 9.216 | 1.124-75.558 | 0.039 |
| Δ IgG | 1.452 | 0.896-2.355 | 0.13 | |||
| COVID-19* | ||||||
| Age | 1.005 | 0.965-1.047 | 0.802 | |||
| Sex | 1.33 | 0.583-3.033 | 0.498 | |||
| Disease duration | 1.09 | 1.025-1.158 | 0.006 | 1.075 | 1.002-1.154 | 0.045 |
| EDSS | 1.211 | 0.976-1.503 | 0.082 | |||
| MS phenotype | 1.071 | 0.454-2.527 | 0.875 | |||
| Δ IgM | 2.369 | 1.014-5.534 | 0.046 | 1.426 | 0.576-3.531 | 0.443 |
| Δ IgG | 0.938 | 0.687-1.280 | 0.686 | |||
⁎
adjusted to possible COVID-19 exposure (from March 2020) and number of COVID-19 vaccines received